- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06231576
Digital Home-Based Prehabilitation Before Surgery (dHOPE)
January 26, 2024 updated by: Vestre Viken Hospital Trust
This clinical trial compares two different prehabilitation programs, with no organized prehabilitation, prior to major colorectal cancer surgery.
The prehabilitation programs include intensive and coached physical exercise and optimized nutritional intake coupled with smoking cessation, physiological support and correction of poly-pharmacy.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients are randomized to either a digital home-based program, a physical hospital-based program or no-organized prehabilitation.
The eligible patients are anyone scheduled for colorectal cancer surgery who are fluent in Norwegian able to consent and to understand questionnaires.
The main question the study aims to answer is whether a digital home-based program is non-inferior to a hospital-based program in terms of improved physical capacity and maintenance of life-quality.
In addition, blood samples will be drawn at three time points, at inclusion, after intervention (prior to surgery) and 6 weeks after surgery to analyze and search for biomarkers reflecting patients' individual surgical risk profile and response to prehabilitation.
Participants randomized to intervention, will be given psychological coaching and support, individualized nutritionist counselling, coached, structured and repeated 60 minutes daily exercises for three weeks prior to surgery.
The control group will receive no organized prehabilitation in the period of time between diagnose and surgery.
Study Type
Interventional
Enrollment (Estimated)
140
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guro Kleve, MD
- Phone Number: +47 32 80 30 00
- Email: guro.kleve@vestreviken.no
Study Contact Backup
- Name: Rune Ougland, MD PhD
- Phone Number: +47 32 80 30 00
- Email: rune.ougland@vestreviken.no
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Planned for major gastrointestinal cancer surgery
- Fluent in Norwegian and able to consent and to understand questionnaires
Exclusion Criteria:
- Inability to walk for six minutes or to rise independently from a chair
- Inability to comprehend exercise program or to comply with written and oral instructions
- Presence of a cardio-pulmonary condition that precludes exercise
- Living in very remote areas making a hospital-based intervention group impossible to implement
- Being without a permanent address
- Admittance to a hospital facility for > 50% of the time from diagnosis to surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hospital
Prehabilitation at the hospital, with guidance by a dedicated physiotherapist physically present.
|
|
|
Experimental: Digital
Prehabilitation at home, with guidance from a dedicated physiotherapist through a digital platform, realtime.
|
|
|
No Intervention: Control
Information about the general benefit of a healthy lifestyle at inclusion, thereafter no further follow-up prior to surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6MWT
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Distance (in meters) walked in 6 minutes
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EuroQol Group Questionnaire 5D (EQ-5D)
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
EQ-5D is a standardized measure of health-related quality of life with 5 dimensions, each dimension represented by a value 1-5 where higher value represents worse outcome.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
|
European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions.
The questionnaire range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
|
Generic Short Patient Experiences Questionnaire (GS-PEQ)
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
GS-PEQ is a questionnaire for collecting data about user experiences across different types of services.
The questionnaire has 12 questions ranging from 1-5; a higher score represents a higher ("better") experience.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
|
Mortality
Time Frame: 3 months after surgery
|
90-day mortality
|
3 months after surgery
|
|
Complications
Time Frame: 3 months after surgery
|
Comprehensive Complication Index (CCI) reflects the gravity of the overall complication burden on the patient on a scale from 0 (no complication) to 100 (death)
|
3 months after surgery
|
|
Need of additional health care support
Time Frame: 4-6 weeks after surgery
|
Use of health care support from the municipality, nursing homes etc
|
4-6 weeks after surgery
|
|
Aggregated length-of-stay (aLoS)
Time Frame: 4-6 weeks after surgery
|
Total time in hospital (from surgery and any readmittance) within 30-days from surgery
|
4-6 weeks after surgery
|
|
Cost-effectiveness
Time Frame: 3 months after surgery
|
An estimation of the resources used on the prehabilitation program will be compared to resources saved by shorter aLoS, less use of nursing home facilities and less need of community healthcare services
|
3 months after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DNA methylation
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Blood samples for DNA methylation profiling will be implemented in a machine learning algorithm to search for biomarkers reliably reflecting frailty and effect of prehabilitation.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
|
RNA methylation
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Blood samples for RNA methylation profiling will be implemented in a machine learning algorithm to search for biomarkers reliably reflecting frailty and effect of prehabilitation.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
|
Metabolome
Time Frame: At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Blood samples for metabolome profiling will be implemented in a machine learning algorithm to search for biomarkers reliably reflecting frailty and effect of prehabilitation.
|
At inclusion, prior to intervention. After intervention, prior to surgery. 4-6 weeks after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rune Ougland, MD PhD, Vestre Viken, Bærum Hospital, Norway
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2030
Study Registration Dates
First Submitted
November 17, 2023
First Submitted That Met QC Criteria
January 26, 2024
First Posted (Actual)
January 30, 2024
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 26, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23/08551
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Protocol and SAP will be published together with results from the pilot study
IPD Sharing Time Frame
By end of 2024
IPD Sharing Access Criteria
Upon request
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.